Treatment of Community-Acquired Pneumonia
For hospitalized adults with moderate-severity community-acquired pneumonia, initiate ceftriaxone 1–2 g IV once daily plus azithromycin 500 mg daily immediately upon diagnosis—this combination reduces mortality compared with β-lactam monotherapy and provides comprehensive coverage of typical and atypical pathogens. 1
Outpatient Management (Previously Healthy Adults)
Amoxicillin 1 g orally three times daily for 5–7 days is the preferred first-line therapy for previously healthy adults without comorbidities, retaining activity against 90–95% of Streptococcus pneumoniae isolates including many penicillin-resistant strains. 1, 2
Doxycycline 100 mg orally twice daily serves as an acceptable alternative when amoxicillin is contraindicated, offering coverage of both typical and atypical organisms. 1, 2
Macrolide monotherapy (azithromycin 500 mg day 1, then 250 mg daily; or clarithromycin 500 mg twice daily) should only be used when local pneumococcal macrolide resistance is documented <25%—in most U.S. regions resistance is 20–30%, making this approach unsafe as first-line therapy. 1, 2
Outpatient Management (Patients with Comorbidities)
Combination therapy is required for adults with comorbidities (COPD, diabetes, chronic heart/liver/renal disease, malignancy, immunosuppression, or recent antibiotic use within 90 days). 1, 2
Preferred regimen: amoxicillin-clavulanate 875/125 mg orally twice daily plus azithromycin (500 mg day 1, then 250 mg daily for 5–7 days), achieving approximately 91.5% favorable clinical outcomes. 1
Alternative: respiratory fluoroquinolone monotherapy (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) should be reserved for patients with β-lactam allergy or when combination therapy is contraindicated, given FDA warnings about serious adverse events (tendon rupture, peripheral neuropathy, aortic dissection). 1, 2
Hospitalized Non-ICU Patients
Two equally effective regimens exist with strong recommendations and high-quality evidence:
The β-lactam plus macrolide combination is preferred over fluoroquinolone monotherapy because systematic reviews demonstrate fewer clinical failures and treatment discontinuations, and it avoids unnecessary fluoroquinolone exposure. 1
For penicillin-allergic patients, respiratory fluoroquinolone is the preferred alternative. 1
Alternative β-lactams include cefotaxime 1–2 g IV every 8 hours or ampicillin-sulbactam 3 g IV every 6 hours, always combined with a macrolide. 1
When aspiration is strongly suspected (alcoholism, altered mental status, dysphagia), ampicillin-sulbactam 3 g IV every 6 hours plus azithromycin provides superior anaerobic coverage compared with ceftriaxone-based regimens. 1
Severe CAP Requiring ICU Admission
Combination therapy is mandatory for all ICU patients—β-lactam monotherapy is linked to significantly higher mortality in critically ill patients with bacteremic pneumococcal pneumonia. 1, 3, 4
Preferred ICU regimen: ceftriaxone 2 g IV daily plus azithromycin 500 mg IV daily (or a respiratory fluoroquinolone: levofloxacin 750 mg IV daily or moxifloxacin 400 mg IV daily). 1, 3
For penicillin-allergic ICU patients, use aztreonam 2 g IV every 8 hours plus a respiratory fluoroquinolone. 1
Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality—consider hydrocortisone 200 mg/day or equivalent for patients with septic shock or ARDS. 3, 4
Special Pathogen Coverage (Risk-Based Only)
Antipseudomonal Coverage
Add antipseudomonal therapy only when specific risk factors are present:
Regimen: piperacillin-tazobactam 4.5 g IV every 6 hours plus ciprofloxacin 400 mg IV every 8 hours (or levofloxacin 750 mg IV daily) plus an aminoglycoside (gentamicin or tobramycin 5–7 mg/kg IV daily) for dual antipseudomonal coverage. 1, 5
MRSA Coverage
Add MRSA therapy only when risk factors exist:
Regimen: vancomycin 15 mg/kg IV every 8–12 hours (target trough 15–20 µg/mL) or linezolid 600 mg IV every 12 hours, added to the base CAP regimen. 1, 5
Duration of Therapy
Minimum treatment duration is 5 days, continuing until the patient is afebrile for 48–72 hours with no more than one sign of clinical instability. 1, 3, 6, 7
For uncomplicated CAP, a total course of 5–7 days is typical. 1, 6, 7
Three-day treatment is validated for non-severe or moderate CAP stabilized at day 3 in patients with clinical improvement (afebrile, respiratory rate ≤24/min, heart rate ≤100 bpm, systolic BP ≥90 mmHg, oxygen saturation ≥90% on room air). 6, 7
Extended courses of 14–21 days are required only for infections caused by Legionella pneumophila, Staphylococcus aureus, or Gram-negative enteric bacilli. 1, 6
Transition from IV to Oral Therapy
Switch from IV to oral antibiotics when the patient is hemodynamically stable (systolic BP ≥90 mmHg, heart rate ≤100 bpm), clinically improving, afebrile for 48–72 hours, respiratory rate ≤24 breaths/min, oxygen saturation ≥90% on room air, and able to take oral medication—typically by hospital day 2–3. 1, 3
Oral step-down options include amoxicillin 1 g three times daily plus azithromycin 500 mg daily (or azithromycin alone after 2–3 days of IV therapy). 1
Critical Timing and Diagnostic Sampling
Administer the first antibiotic dose immediately upon diagnosis, ideally in the emergency department—delays beyond 8 hours increase 30-day mortality by 20–30% in hospitalized patients. 1, 3
Obtain blood cultures and sputum Gram stain/culture before initiating antibiotics in all hospitalized patients to enable pathogen-directed therapy and safe de-escalation. 1, 8
All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (antiviral therapy) and infection prevention strategies. 3
Monitoring and Reassessment
Monitor temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation at least twice daily in hospitalized patients to detect early deterioration. 1
If no clinical improvement by day 2–3, obtain repeat chest radiograph, inflammatory markers (CRP, white blood cell count), and additional microbiologic specimens to evaluate for complications such as pleural effusion, empyema, or resistant organisms. 1
For non-severe pneumonia initially treated with amoxicillin monotherapy that fails, add or substitute a macrolide to provide atypical pathogen coverage. 1
For non-severe pneumonia on combination therapy that fails, switch to a respiratory fluoroquinolone. 1
Common Pitfalls to Avoid
Never use macrolide monotherapy in hospitalized patients—it fails to cover typical pathogens such as S. pneumoniae and is associated with treatment failure and breakthrough bacteremia. 1
Avoid indiscriminate fluoroquinolone use in uncomplicated outpatient CAP due to FDA warnings about serious adverse events and rising resistance; reserve for patients with comorbidities or treatment failure. 1, 2
Do not add broad-spectrum antipseudomonal or MRSA agents routinely—restrict their use to patients with documented risk factors to prevent unnecessary resistance, adverse effects, and cost. 1, 5
Do not extend therapy beyond 7–8 days in responding patients without specific indications, as longer courses increase antimicrobial resistance risk without improving outcomes. 1, 6
Oral cephalosporins (cefuroxime, cefpodoxime) should not be used as first-line agents for CAP because of inferior in-vitro activity against S. pneumoniae compared with high-dose amoxicillin or IV ceftriaxone. 1
Severity Assessment and Site-of-Care Decision
Use validated severity scores (Pneumonia Severity Index or CURB-65) together with clinical judgment to determine whether hospitalization is required. 1, 2, 5
PSI classes I–III are appropriate for outpatient care; PSI classes IV–V require hospitalization. 1
ICU admission is indicated when any one major criterion is present (septic shock requiring vasopressors or respiratory failure requiring mechanical ventilation) or when ≥3 minor criteria are met (confusion, respiratory rate ≥30/min, systolic BP <90 mmHg, multilobar infiltrates, PaO₂/FiO₂ <250). 1, 5
Prevention
Offer pneumococcal polysaccharide vaccine to all adults ≥65 years and those with high-risk conditions—administer 20-valent pneumococcal conjugate vaccine alone or 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine one year later. 1, 2
Recommend annual influenza vaccination for all patients. 1, 2
Provide smoking-cessation counseling to all current smokers. 1